Radiopharm Theranostics Limited balance sheet RADX

Annual Quarterly

As of Jun 30, 2025, Radiopharm Theranostics Limited had total assets of $86.5 million and total liabilities of $43.6 million. Stockholders' equity was $42.9 million. Cash and investments were $29.1 million. The current ratio, current assets divided by current liabilities, was 2.67.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

FY 2025
Jun 30, 2025
Assets
Cash
29
Cash and investments
29
Receivables
10
Total current assets
40
Property and equipment, net
0
Total assets
86
Liabilities and equity
Accounts payable
9
Total current liabilities
15
Total liabilities
44
Stockholders' equity
43
Ratios
Current ratio
2.67x
Return on equity
-89.43%
Return on assets
-44.34%
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
RADX (Nasdaq), RDPTF (OTC)
Fiscal year ends
June 30
Incorporated in
Australia
Headquarters
Carlton Vic
SEC filer status
Non-accelerated filer, Emerging growth company
SEC CIK
1949257

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.